TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

Contrary to conventional bolus injections which cause fluctuating VEGF suppression, this method allows steady, localized inhibition and may maintain therapeutic levels for years with a single dose.

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

which comprises a wearable insulin delivery patch for injection-free bolus dosing. CeQur plans to put the latest funding towards scaling its commercial teams and outreach initiatives to bring ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...